MX2017003377A - Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado. - Google Patents

Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado.

Info

Publication number
MX2017003377A
MX2017003377A MX2017003377A MX2017003377A MX2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A
Authority
MX
Mexico
Prior art keywords
codon
recombinant plasmid
humans
optimized recombinant
gene therapeutic
Prior art date
Application number
MX2017003377A
Other languages
English (en)
Inventor
Vadimovich Deev Roman
Aleksandrovich ISAEV Artur
Yadigerovich Bozo Ilya
Anatolyevich Rizvanov Albert
Faridovich MASGUTOV Ruslan
Andreevich Bogov Aleksei
Ildusovich SALAFUTDINOV Ilnur
Leonidovich Plaksa Igor
Alekseevich BOGOV Andrei
Original Assignee
Nextgen Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextgen Company Ltd filed Critical Nextgen Company Ltd
Publication of MX2017003377A publication Critical patent/MX2017003377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a ingeniería génica así como medicina, específicamente, neurocirugía y traumatología. La invención describe una estructura terapéutica de gen que codifica un factor de crecimiento endotelial vascular (VEGF) y un factor de crecimiento de fibroblasto (FGF-2). El plásmido recombinante con codón optimizado es el componente activo de la estructura terapéutica de gen que codifica ambos factores. Una estructura terapéutica de gen podría ser administrada directamente en un nervio dañado y los tejidos paraneurales tanto en períodos intraoperativos como pos-operativos. La invención se propone para estimular la regeneración de nervios. La invención significativamente mejora los resultados de un tratamiento de nervio periférico lesionado.
MX2017003377A 2014-09-16 2015-08-27 Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado. MX2017003377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014137218/10A RU2558294C1 (ru) 2014-09-16 2014-09-16 Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека
PCT/RU2015/000545 WO2016163912A1 (ru) 2014-09-16 2015-08-27 Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека

Publications (1)

Publication Number Publication Date
MX2017003377A true MX2017003377A (es) 2017-11-22

Family

ID=53762789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003377A MX2017003377A (es) 2014-09-16 2015-08-27 Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado.

Country Status (10)

Country Link
US (2) US20170189488A1 (es)
EP (1) EP3196307B1 (es)
JP (1) JP6540797B2 (es)
CN (1) CN107087417A (es)
AU (1) AU2015390821B2 (es)
BR (1) BR112017005310B1 (es)
CA (1) CA2960371C (es)
MX (1) MX2017003377A (es)
RU (1) RU2558294C1 (es)
WO (1) WO2016163912A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2614665C1 (ru) * 2015-12-18 2017-03-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа
KR102592673B1 (ko) 2016-05-25 2023-10-24 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역요법의 방법
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
CA3050299A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
RU2762855C1 (ru) * 2021-04-08 2021-12-23 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генно-клеточный везикулярный терапевтический препарат и способ терапии рассеянного склероза посредством трансплантации генно-клеточного везикулярного терапевтического препарата

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418346T1 (de) * 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
RU2459630C1 (ru) * 2011-04-27 2012-08-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) Способ стимулирования нейрогенерации с помощью генетических конструкций
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций

Also Published As

Publication number Publication date
CA2960371C (en) 2019-06-25
RU2558294C1 (ru) 2015-07-27
US10434145B2 (en) 2019-10-08
JP2017532021A (ja) 2017-11-02
WO2016163912A1 (ru) 2016-10-13
US20170319658A1 (en) 2017-11-09
AU2015390821B2 (en) 2018-08-09
AU2015390821A1 (en) 2017-05-04
CN107087417A (zh) 2017-08-22
EP3196307A1 (en) 2017-07-26
BR112017005310B1 (pt) 2023-10-03
CA2960371A1 (en) 2016-10-13
BR112017005310A2 (pt) 2018-02-14
JP6540797B2 (ja) 2019-07-10
EP3196307B1 (en) 2018-12-26
US20170189488A1 (en) 2017-07-06
EP3196307A4 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2017003377A (es) Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
WO2016113357A8 (en) Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer
MX2018005286A (es) Constructo genetico.
SG10201808218YA (en) Gene therapy for retinitis pigmentosa
WO2012170805A3 (en) Instruments and devices for subchondral joint repair
NZ750363A (en) Tissue use for repair of injury
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
EP3624731A4 (en) TARGETED IN-SITU THERAPEUTIC ADMINISTRATION OF SECRETED FACTORS FROM STEM CELLS FOR THE TREATMENT OF INJURED TISSUES
MX2023008504A (es) Inhibidores del factor de crecimiento endotelial vascular (vegf) para usarse en el tratamiento de degeneracion macular humeda.
EP3488877A4 (en) IMPLANT AND KIT FOR TREATING BONE LESION SITES AND METHOD FOR TREATING LESION SITES
AU2018236629A8 (en) Hydrogel patch
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
IL267958B1 (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
EP4309635A3 (en) Surgical tool for ocular tissue transplantation
MX2019003751A (es) Proteina terapeutica.
EP3116594A4 (en) System for stimulating bone growth, tissue healing and/or pain control, and method of use
TW201613639A (en) Methods for treating cardiovascular diseases
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EP3813854A4 (en) IN VIVO CONTROLLED COMBINATION THERAPY FOR THE TREATMENT OF CANCER
EP3541418A4 (en) THERAPY WITH AUTOLOGICAL SOMATIC STEM CELLS, METHOD FOR THE CONTROLLABLE MANUFACTURING OF A THERAPEUTIC COMPOSITION AND PROCEDURE OF ADAPTIVE TREATMENT OF AN IVF PATIENT
GB201314859D0 (en) Molecular targets for healing or treating wounds
EP3426337A4 (en) METHOD AND DEVICES FOR STIMULATING BLOOD VESSELS FOR CONTROLLING, TREATING AND / OR PREVENTING BLEEDING